MOUNTAIN VIEW, Calif., April 15, 2014 /PRNewswire/ —

Companies along the spectrum of life science tools, informatics, genomics services, and clinical diagnostics industries continue flocking to the next-generation sequencing (NGS) market to take advantage of double-digit growth and an industry potentially worth billions in the coming years. Yet can this booming industry really support the more than 100 competitors and counting that serve the NGS informatics, data analysis, biological interpretation and clinical reporting portion of the market? It is imperative to evaluate the changing competitive landscape and uncover the real market information behind the hype to assess future market development.

Discussion Points

• Will it be considered malpractice to diagnose and treat patients in 2020 without taking into account their individual genomic and proteomic data?
• At what point does sequencing each individual’s genome become the standard of care?
• What are the real market opportunities and growth expectations?
• What are the mileposts to look for along the path to NGS market transformation?

Supporting Quote

“Many large clinical organizations have ambitious plans for clinical sequencing, for example, sequencing every patient who walks in the door; however, payors must be on board for the market to truly take off,” says Frost & Sullivan Senior Vice President of Healthcare and Life Sciences Greg Caressi. “Substantial evidence demonstrating sequencing’s value and cost-savings advantages is necessary before it becomes routine in practices globally. Additionally, many chief information officers will take at least five years to realize the need for investing in clinical informatics with links to electronic health records. Because hospital administrators tend to think in terms of long-term investment cycles, this mentality will not take hold for many years.”

Registration

• Attend the presentation at Bio-IT World Conference & Expo ’14 by visiting: http://bit.ly/1mYbtx6

Supporting Resources

For more information about Frost & Sullivan’s global Healthcare practice, please visit: http://www.healthcare.frost.com.

About Bio-IT World

Part of the Cambridge Healthtech Institute Media Group, Bio-IT World provides outstanding coverage of cutting-edge trends and technologies that impact the management and analysis of life sciences data, including next-generation sequencing, drug discovery, predictive and systems biology, informatics tools, clinical trials, and personalized medicine. Through a variety of sources including, Bio-ITWorld.com, Weekly Update Newsletter and the Bio-IT World News Bulletins, Bio-IT World is a leading source of news and opinion on technology and strategic innovation in the life sciences, including drug discovery and development. http://www.Bio-ITWorld.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the Global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies? Contact us: Start the discussion (www.Frost.com)

Contact:
Jennifer Carson
Frost & Sullivan
+1.210.247.2450
jennifer.carson@frost.com

SOURCE Frost & Sullivan